NeuroOne updates $13.4M at-the-market stock program
NeuroOne Medical Technologies Corporation is updating its at-the-market stock offering, filing a Prospectus Supplement for the offer and sale of up to $13.4 million of common shares through JonesTrading under its existing Capital on Demand Sales Agreement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
NeuroOne Medical Technologies Corporation is updating its at-the-market stock offering, filing a Prospectus Supplement for the offer and sale of up to $13.4 million of common shares through JonesTrading under its existing Capital on Demand Sales Agreement.
The shares will be issued under an effective registration statement, with sales made only by means of the updated prospectus. Honigman LLP provided a legal opinion on the validity of the shares, which is included as an exhibit to this report.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM capacity: $13.4 million of common stock
Par value: $0.001 per share
Sales Agreement date: December 21, 2022
+1 more
4 metrics
ATM capacity
$13.4 million of common stock
Maximum aggregate amount of shares offered under updated Prospectus Supplement
Par value
$0.001 per share
Par value of NeuroOne Medical Technologies common stock
Sales Agreement date
December 21, 2022
Date NeuroOne entered Capital on Demand Sales Agreement with JonesTrading
Prospectus update date
June 12, 2026
Date updated Prospectus Supplement for ATM program was filed
Key Terms
Capital on Demand Sales Agreement, at the market offering, Rule 415(a)(4), Prospectus Supplement, +1 more
5 terms
Capital on Demand Sales Agreement financial
"entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading"
at the market offering regulatory
"through any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Rule 415(a)(4) regulatory
"deemed an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act"
Rule 415(a)(4) is a U.S. Securities and Exchange Commission rule that lets a company add more securities to an already effective shelf registration, so those additional shares or bonds can be sold later without filing a completely new registration. For investors it matters because it gives the issuer the flexibility to raise cash quickly—like having an open credit line—while creating the possibility of dilution or changes in supply that can affect share price.
Prospectus Supplement financial
"filed an updated Prospectus Supplement (the “Prospectus”) for the offer and sale"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Registration Statement regulatory
"The Shares will be sold pursuant to the Registration Statement"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeuroOne Medical Technologies (NMTC) announce in this 8-K filing?
NeuroOne Medical Technologies filed an updated Prospectus Supplement to continue selling common stock under its at-the-market program. The company may offer and sell up to $13.4 million of shares through JonesTrading under a previously signed Capital on Demand Sales Agreement.
How much stock can NeuroOne Medical Technologies (NMTC) sell under the updated prospectus?
The updated prospectus allows NeuroOne Medical Technologies to offer and sell up to $13.4 million of common shares. These sales will occur through JonesTrading as sales agent under the existing Capital on Demand Sales Agreement, using an at-the-market offering structure.
What is the role of JonesTrading in NeuroOne Medical Technologies (NMTC)'s ATM program?
JonesTrading Institutional Services LLC acts as sales agent for NeuroOne Medical Technologies’ at-the-market offering. It may sell the company’s common stock from time to time using methods that qualify as an at-the-market offering under Rule 415(a)(4) of the Securities Act.
Is NeuroOne Medical Technologies (NMTC)'s updated prospectus itself an offer to sell securities?
The filing states it does not itself constitute an offer to sell or a solicitation to buy securities. Any sales of NeuroOne Medical Technologies’ common stock must comply with applicable state securities laws and will be made only by means of the Prospectus Supplement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates